Turin

• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus … Ended recruitment
  2024-518869-99-00 4 2025-11-17 Cushing's disease
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Ended recruitment
  2024-511754-41-00 4 2025-05-29 idiopathic pulmonary fibrosis
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended recruitment
  2024-513738-39-00 9 2025-03-18 IDH1-mutant Glioma
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma
• Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch Ended recruitment
  2023-509751-14-03 4 2025-02-27 HIV
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• PENTALLO (PENTAglobin in Acute Leukemia and ALLOgeneic transplants) Ended recruitment
  2024-518940-19-02 4 2025-01-28 Acute Myeloid Leukemia (AML)
• Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger … Ended recruitment
  2024-516316-13-00 4 2025-01-21 Merkel cell carcinoma without metastases in other organs and surgicall
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• A trial to evaluate efficacy and safety of buloxibutid in people with idiopathic pulmonary fibrosis Ended recruitment
  2023-509069-19-00 4 2024-12-12 idiopathic pulmonary fibrosis
• ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended recruitment
  2024-518669-83-00 4 2024-12-05 acute promyelocytic leukemia (APL) in children and adolescents
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema … Ended recruitment
  2024-510944-30-00 10 2024-11-22 Diabetic Macular Edema
• Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended recruitment
  2022-501457-37-00 5 2024-10-28 Myeloid Leukemia in Children with Down Syndrome
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Ended recruitment
  2023-506049-52-00 4 2024-10-28 Follicular lymphoma
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended recruitment
  2024-510584-37-00 4 2024-10-22 Systemic Lupus Erythematosus
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL … Ended recruitment
  2024-511627-34-00 4 2024-10-17 Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

Showing 337–360 of 632 trials